Stimulant treatment for ADHD not associated with increased risk of cardiac events in youth

Attention-deficit/hyperactivity disorder (ADHD) affects 5-9% of youth and is frequently treated with stimulant medications, such as methylphenidate and amphetamine products. A recent safety communication from the US Food and Drug Administration advised that all patients undergoing ADHD treatment be monitored for changes in heart rate or blood pressure.

Amidst growing concern over the risks of stimulant use in youth, a study by Dr. Mark Olfson of the New York State Psychiatric Institute and Columbia University, and his colleagues, published in the February 2012 issue of the Journal of the American Academy of Child and Adolescent Psychiatry, assessed the risk of adverse cardiovascular events in children and adolescents without known heart conditions treated with stimulants for ADHD. It is one of the largest studies to date focusing primarily on youth while controlling for pre-existing .

As reported in the study, Olfson and colleagues examined claims records from a large privately insured population for associations between cardiovascular events in youth with ADHD and stimulant treatment. In total 171,126 privately insured youth aged 6-21 years without known pre-existing heart-related risk factors were followed throughout the study.

The study included patients who have previously received stimulant treatment, patients currently receiving stimulant treatment, and patients who began or ceased stimulant treatments during the study period. Olfson and colleagues assessed the various groups for incidents of severe cardiovascular events such as , less severe cardiovascular events such as cardiac dysrhythmias, and cardiovascular symptoms such as tachycardia and palpitations. Analysis showed that cardiovascular events and symptoms were rare in this cohort and not associated with stimulant use.

This finding helps to allay concerns of adverse events in otherwise healthy young people receiving treatment for ADHD. Olfson and colleagues said of the results, "It is reassuring that in these young people, short-term stimulant treatment did not substantially increase the risk of or symptoms."

More information: The article, "Stimulants and Cardiovascular Events in Youth With Attention-Deficit/Hyperactivity Disorder" by Mark Olfson, Cecilia Huang, Tobias Gerhard, Almut G. Winterstein, Stephen Crystal, Paul D. Allison, Steven C. Marcus (doi:10.1016/j.jaac.2011.11.008) appears in Journal of the American Academy of Child and Adolescent Psychiatry, Volume 51, Issue 2 (February 2012)

add to favorites email to friend print save as pdf

Related Stories

Prescribed stimulant use for ADHD continues to rise steadily

Sep 28, 2011

The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and ...

Mutant gene linked to ADHD

Apr 18, 2011

(PhysOrg.com) -- In a recent study published in Nature Medicine, Dr. Eunjin Kim from the Korea Advanced Institute of Science and Technology uncovers a genetic fault that triples the chances of a child having ADHD (Attention Defici ...

Recommended for you

User comments